{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:51:09Z","timestamp":1791409869375,"version":"4.3.3"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Republic of Serbia Ministry of Education Science and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003193","name":"Ministry of Education Science Research and Sport of the Slovak Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003193","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110332","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:42:18Z","timestamp":1785825738000},"page":"110332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design of fluorinated triazinoindoles as highly potent and markedly selective ALR2 inhibitors: synthesis, in silico and in vitro evaluation of promising lead compounds"],"prefix":"10.1016","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8075-6307","authenticated-orcid":false,"given":"Lucia","family":"Kovacikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terezia","family":"Teplanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Majekova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambroz","family":"Almassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Addova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Hanquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Pannosian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Dobricic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Bohac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110332_bb0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110332_bb0010","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2026.110332_bb0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/1389450054021891","article-title":"Aldose reductase in diabetic microvascular complications","volume":"6","author":"Chung","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2026.110332_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0031-6997(24)01347-4","article-title":"Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications","volume":"50","author":"Yabe-Nishimura","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2026.110332_bb0025","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2337\/diabetes.54.12.3435","article-title":"Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited","volume":"54","author":"Obrosova","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2026.110332_bb0030","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1021\/jm500907a","article-title":"Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions","volume":"58","author":"Maccari","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0035","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2174\/1389201025666230830125147","article-title":"The role of aldose reductase in polyol pathway: an emerging pharmacological target in diabetic complications and associated morbidities","volume":"25","author":"Gupta","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bioorg.2026.110332_bb0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1515\/bmc.2011.002","article-title":"Aldose reductase: new insights for an old enzyme","volume":"2","author":"Ramana","year":"2011","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.bioorg.2026.110332_bb0045","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cbi.2011.02.023","article-title":"Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders","volume":"191","author":"Srivastava","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110332_bb0050","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1210\/endo.139.8.6152","article-title":"Effect of Epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats","volume":"139","author":"Kashima","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.bioorg.2026.110332_bb0055","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1021\/jm00145a001","article-title":"Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications","volume":"28","author":"Kador","year":"1985","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/jm00105a018","article-title":"Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners","volume":"34","author":"Mylari","year":"1991","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0065","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1021\/jm0492094","article-title":"Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (Lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications","volume":"48","author":"van Zandt","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ahj.2021.10.022","article-title":"A pilot open-label study of aldose reductase inhibition with AT-001 (Caficrestat) in patients hospitalized for COVID-19 infection: results from a registry-based matched-control analysis","volume":"242","author":"Gaztanaga","year":"2021","journal-title":"Am. Heart J."},{"key":"10.1016\/j.bioorg.2026.110332_bb0075","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/13543776.2024.2412573","article-title":"The challenging inhibition of aldose reductase for the treatment of diabetic complications: a 2019\u20132023 update of the patent literature","volume":"34","author":"Bernardoni","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110332_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2019.1582646","article-title":"Aldose reductase inhibitors: 2013\u2013present","volume":"29","author":"Quattrini","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110332_bb0085","doi-asserted-by":"crossref","first-page":"9295","DOI":"10.1039\/D3CP05985E","article-title":"Decoding selectivity: computational insights into AKR1B1 and AKR1B10 inhibition","volume":"26","author":"Liu","year":"2024","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.bioorg.2026.110332_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139207","article-title":"Selectivity challenges for aldose reductase inhibitors: a review on comparative SAR and interaction studies","volume":"1318","author":"Kumari","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.110332_bb0095","first-page":"864","article-title":"Medicinal perspective of indole derivatives: recent developments and structure-activity relationship studies","volume":"21","author":"Kumar","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2026.110332_bb0100","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1021\/jm0109210","article-title":"[1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors","volume":"44","author":"Da Settimo","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/acs.jmedchem.9b01747","article-title":"Development of novel oxotriazinoindole inhibitors of aldose reductase: isosteric sulfur\/oxygen replacement in the thioxotriazinoindole cemtirestat markedly improved inhibition selectivity","volume":"63","author":"Hlav\u00e1\u010d","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115885","article-title":"Novel substituted N-benzyl(oxotriazinoindole) inhibitors of aldose reductase exploiting ALR2 unoccupied interactive pocket","volume":"29","author":"Hlav\u00e1\u010d","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0115","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s00044-024-03194-3","article-title":"Selectivity of N(2)-substituted oxotriazinoindole aldose reductase inhibitors is determined by the interaction pattern with Pro301-Arg312 loop of aldehyde reductase","volume":"33","author":"Kov\u00e1\u010dikov\u00e1","year":"2024","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.110332_bb0120","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1021\/acs.jmedchem.9b01877","article-title":"Metabolic and pharmaceutical aspects of fluorinated compounds","volume":"63","author":"Johnson","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0125","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0130","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0135","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1016\/j.bmc.2008.01.042","article-title":"Design and synthesis of N-(3,5-Difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors","volume":"16","author":"Alexiou","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0140","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1021\/jm9802968","article-title":"Novel, highly potent aldose reductase inhibitors: (R)-(\u2212)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3\u2032-pyrrolidine-1,2\u2032,3,5\u2032-tetrone (AS-3201) and its congeners","volume":"41","author":"Negoro","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0145","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/jm5015814","article-title":"Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold","volume":"58","author":"Stefek","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0150","doi-asserted-by":"crossref","first-page":"587","DOI":"10.33549\/physiolres.933034","article-title":"A novel carboxymethylated mercaptotriazinoindole inhibitor of aldose reductase interferes with the polyol pathway in streptozotocin-induced diabetic rats","volume":"64","author":"Prnova","year":"2015","journal-title":"Physiol. Res."},{"key":"10.1016\/j.bioorg.2026.110332_bb0155","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1179\/1351000215Y.0000000019","article-title":"Antioxidant action of 3-mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid, an efficient aldose reductase inhibitor, in a 1,1\u2032-diphenyl-2-picrylhydrazyl assay and in the cellular system of isolated erythrocytes exposed to tert-butyl hydroperoxide","volume":"20","author":"Prnova","year":"2015","journal-title":"Redox Rep."},{"key":"10.1016\/j.bioorg.2026.110332_bb0160","first-page":"41","article-title":"Cemtirestat, a novel aldose reductase inhibitor and antioxidant, in multitarget pharmacology of diabetic complications","volume":"4","author":"Stefek","year":"2016","journal-title":"Int. J. Adv. in Sci., Eng. and Tech. IRAJ"},{"key":"10.1016\/j.bioorg.2026.110332_bb0165","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s11064-019-02736-1","article-title":"3-Mercapto-5H-1,2,4-Triazino[5,6-b]Indole-5-acetic acid (Cemtirestat) alleviates symptoms of peripheral diabetic neuropathy in Zucker diabetic fatty (ZDF) rats: a role of aldose reductase","volume":"44","author":"Prnova","year":"2019","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bioorg.2026.110332_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10715762.2023.2298852","article-title":"Cemtirestat dimerization in liposomes and erythrocytes exposed to peroxyl radicals was reverted by thiol-disulfide exchange with GSH","volume":"58","author":"Kovacikova","year":"2024","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.bioorg.2026.110332_bb0175","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1021\/cb400526n","article-title":"Modulation of aldose reductase inhibition by halogen bond tuning","volume":"8","author":"Fanfrl\u00edk","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110332_bb0180","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2174\/092986709787458362","article-title":"Aldose reductase enzyme and its implication to major health problems of the 21(st) century","volume":"16","author":"Alexiou","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0185","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0753-3322(96)82629-1","article-title":"New approaches for treatment in diabetes: aldose reductase inhibitors","volume":"49","author":"Hotta","year":"1995","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110332_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.0.CO;2-7","article-title":"Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches","volume":"19","author":"Costantino","year":"1999","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110332_bb0195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/13543776.12.5.621","article-title":"Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications","volume":"12","author":"Miyamoto","year":"2002","journal-title":"Expert Opin. Ther. Patents"},{"key":"10.1016\/j.bioorg.2026.110332_bb0200","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1210\/er.2004-0028","article-title":"Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options","volume":"26","author":"Srivastava","year":"2005","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bioorg.2026.110332_bb0205","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1592\/phco.28.5.646","article-title":"Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy","volume":"28","author":"Ramirez","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bioorg.2026.110332_bb0210","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1517\/13543776.2012.726615","article-title":"Novel aldose reductase inhibitors: a patent survey (2006-present)","volume":"22","author":"Chatzopoulou","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110332_bb0215","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1389557515666150909143737","article-title":"Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases","volume":"16","author":"Grewal","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0220","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ejmech.2009.12.019","article-title":"Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor","volume":"45","author":"Carbone","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0225","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/03602530802431439","article-title":"The Aldo-keto reductase superfamily and its role in drug metabolism and detoxification","volume":"40","author":"Barski","year":"2008","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bioorg.2026.110332_bb0230","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cbi.2011.02.007","article-title":"Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde","volume":"191","author":"Ruiz","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110332_bb0235","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/1811199a0","article-title":"Antioxidant determinations by the use of a stable free radical","volume":"181","author":"Blois","year":"1958","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110332_bb0245","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4155\/fmc-2018-0127","article-title":"Ligand-based drug design of novel aldose reductase inhibitors","volume":"10","author":"Majekova","year":"2018","journal-title":"Fut. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0250","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/molecules26102867","article-title":"Development of novel indole-based bifunctional aldose reductase inhibitors\/antioxidants as promising drugs for the treatment of diabetic complications","volume":"26","author":"Kovacikova","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110332_bb0255","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/jm00032a011","article-title":"Molecular modeling studies of aldose reductase inhibitors","volume":"37","author":"Lee","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0260","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1039\/B517914A","article-title":"Advances in methods and algorithms in a modern quantum chemistry program package","volume":"8","author":"Shao","year":"2006","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.bioorg.2026.110332_bb0265","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802608786786624","article-title":"Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery","volume":"8","author":"Vilar","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0270","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcc.23899","article-title":"New ways to boost molecular dynamics simulations","volume":"36","author":"Krieger","year":"2015","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110332_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117035","article-title":"Rational design and synthesis of novel N-benzylindole-based epalrestat analogs as selective aldose reductase inhibitors: an unexpected discovery of a new glucose-lowering agent (AK-4) acting as a mitochondrial uncoupler","volume":"281","author":"Kousaxidis","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:07:03Z","timestamp":1791407223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"alternative-id":["S0045206826008680"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110332","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of fluorinated triazinoindoles as highly potent and markedly selective ALR2 inhibitors: synthesis, in silico and in vitro evaluation of promising lead compounds","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110332"}}